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Background: Pulmonary fibrosis is an untreatable, fatal disease characterized by excess deposition of extracellular
matrix and inflammation. Although the etiology of pulmonary fibrosis is unknown, recent studies have implicated
dysregulated immune responses and wound healing. Since n-3 polyunsaturated fatty acids (n-3 PUFAs) may
beneficially modulate immune responses in a variety of inflammatory disorders, we investigated the therapeutic
role of docosahexaenoic acid (DHA), a single n-3 PUFA, in lung fibrosis.
Methods: Intratracheal DHA or PBS was administered to mouse lungs 4 days prior to intratracheal bleomycin
treatment. Body weight and survival were monitored for 21 days. Bronchoalveolar fluid (BALF) and lung inflammatory
cells, cytokines, eicosanoids, histology and lung function were determined on serial days (0, 3, 7, 14, 21) after bleomycin
injury.
Results: Intratracheal administration of DHA mitigated bleomycin-induced lung injury. Mice pretreated with DHA had
significantly less weight loss and mortality after bleomycin injury. The lungs from DHA-pretreated mice had markedly
less fibrosis. DHA pretreatment also protected the mice from the functional changes associated with bleomycin injury.
Bleomycin-induced cellular inflammation in BALF and lung tissue was blunted by DHA pretreatment. These
advantageous effects of DHA pretreatment were associated with decreased IL-6, LTB4, PGE2 and increased IL-10.
Conclusions: Our findings demonstrate that intratracheal administration of DHA, a single PUFA, protected mice from
the development of bleomycin-induced pulmonary inflammation and fibrosis. These results suggest that further
investigations regarding the role of n-3 polyunsaturated fatty acids in fibrotic lung injury and repair are needed.Background
Idiopathic Pulmonary fibrosis (IPF) is a relentless and pro-
gressive disease characterized by lung inflammation and
subsequent fibrosis [1,2]. A critical barrier to treating this
disease is the lack of understanding of the pathophysiology
driving the fibrosis. In pulmonary fibrosis, the normally
self-limiting lung inflammation that results in healing and
restoration of tissue integrity becomes an unremitting in-
flammation characterized by persistent inflammatory cell
infiltration, fibroblast recruitment and ensuing fibrosis
[3,4]. Although the etiology of this persistent inflamma-
tion is unclear, it is clear that this disease is associated
with the persistence of pro-inflammatory cytokines and* Correspondence: mhorton2@jhmi.edu
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unless otherwise stated.chemokines. Specifically, TNF-α, TGF-β, and both CXC
chemokines (IL-8, MIG, IP-10, I-TAC) as well as CC che-
mokines (MIP-1, MCP-1) [5]. Recently, inflammatory lipid
eicosanoid mediators, such as prostaglandins (PGs) and
leukotrienes (LTs), have also been linked to pulmonary
fibrosis [6-10].
Fish oil, a complex mixture of polyunsaturated fatty
acids as well as a range of other unsaturated and saturated
fatty acids, has been deemed beneficial in a wide variety of
human chronic ailments [11-16]. Unfortunately, due to
the complex mixture of fats in the fish oil, many of the
purported benefits have been recently questioned [17-26].
Thus, investigating a single, pure polyunsaturated fatty
acid (PUFA) is pivotal in understanding its role in dis-
eases. Recent studies have showed that a pure n-3 PUFA
may exert beneficial effects in inflammatory ailments
[27-31]. The pure n-3 PUFAs have been noted to reducetd. This is an Open Access article distributed under the terms of the Creative
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such as IL-6 and TNF-α and suppress the production of
prostaglandins (PGs) and leukotrienes (LTs) [31-35]. It is
believed that the beneficial effects of n-3 PUFAs are due
in part to the replacement of arachidonic acid in the
membrane phospholipids of inflammatory cells with the
n-3 PUFAs thus leading to a reduced capacity of immune
cells to synthesize LTs and PGs [36,37]. At present, the
specific effects of n-3 PUFAs on pulmonary fibrosis have
not been studied. In this study, we demonstrate that
DHA, one best-known n-3 PUFA, protects mice from
bleomycin-induced pulmonary inflammation and fibrosis.
Intratracheal DHA mitigated bleomycin induced mor-
tality, weight loss, inflammation, histological damage and
loss of lung function. Overall these findings provide
insight into the disease process as well as suggest a novel
therapeutic approach for pulmonary fibrosis.Methods
Reagents
DHA was purchased from Sigma-Alrich (St. Louis, MO),
bleomycin from Hospira (Lake Forest, IL) and antibodies
from eBiosceice (San Diego, CA) and Cayman (Ann
Arbor, MI).Animals
In this study, 8 week old female C57BL/6 mice were
purchased from Jackson Laboratories (Bar Harbor, ME),
housed in a pathogen-free sterile facility at the Johns
Hopkins School of Public Health and allowed water and
food ad libitum. All animal experiments were approved
by the Johns Hopkins Animal Care and Use Committee.Pulmonary fibrosis model
8 week old female C57BL/6 mice were anesthetized by
intraperitoneal injection of 75 mg/kg ketamine and
5 mg/kg xylazine, intubated and given 50 μl of PBS or
DHA (6.25 mg/kg body weight) diluted in PBS intrata-
cheally. 4 days after DHA or PBS treatment, mice were
again anesthesized, intubated and given intratracheal
bleomycin (1.5 U/kg or 2.5 U/kg) in 50 μl PBS. Body
weight and survival were monitored. Mice were sacri-
ficed for bronchoalveolar lavage, FACS, histology and
lung function measurements at days 0, 3, 7, 14 and 21
after bleomycin. Day 0 represents baseline, i.e. 4 days
after DHA or PBS, but prior to bleomycin.BALF cell count
BALF differential cell counts were carried out through
cytopspin preparation (Thermo Scientific, Waltham, MA)
and Diff-Quick Staining (Dade Behring; Germany).Flow cytometry
All flow cytometry of lung cells was performed on a Facs
Caliber, BD Biosciences (San Jose, CA). FACS antibodies
were purchased from eBiosceice (San Diego, CA).
ELISA
IFN-γ, TNF-α, IL-1, IL-6, IL-10 and IL-33 were measured
in BALF by ELISA according to the manufacturer’s proto-
col (eBioscience, San Diego, CA). Leukotriene B4 (LTB4),
and prostaglandin E2 (PGE2) were measured with immu-
noassays per protocol from Cayman (Ann Arbor, MI).
Lung function measurement
Using the forced oscillation technique, tissue elastance
(H) and tissue damping (G) that reflect the severity of
pulmonary fibrosis were measured [10,38]. All dynamic
measurements were performed in vivo on anesthetized
mice (intraperitoneal 100 mg/kg ketamine and 10 mg/kg
xylazine) with an intact chest wall. After animals were
anesthetized, tracheotomy and intubation was performed
and the animals were ventilated by a computerized
Flexivent system (SCIREQ Scientific respiratory equip-
ment, Montreal, Quebec, Canada) with a tidal volume of
0.2 ml of 100% oxygen at a rate of 150 breaths/min.
After administration of succinylcholine (2 mg/kg), a
deep inspiration (DI) was given and held for 5 seconds,
prior to returning to normal ventilation. One minute
after the DI, measurement was performed and data were
fit into constant phase model to determine G and H.
Histology and imaging
Following assessment of lung function, the lungs were
inflated at a pressure of 25 cmH2O with formalin, sec-
tioned and stained with Hematoxylin-eosin (H&E) for
lung morphology and Masson’s trichrome to observe
collagen deposition. The sections were photographed at
20X magnification to create panorama images which
were scored for fibrosis by Ashcroft method as pre-
viously described [39].
Statistics
Data were and analyzed with the Mann–Whitney U-test
running Prism software (GraphPad Inc., San Diego, CA).
P values < 0.05 were considered significant. Survival
curves (Kaplan-Meier plots) were compared using a log
rank test.
Results
Intratracheal DHA enhances survival following bleomycin
injury
We hypothesized that administration of DHA, a pure
single n-3 polyunsaturated acid, would mitigate bleo-
mycin-induced injury in mice. As pure n-3 PUFA is
not stable and highly prone to oxidation, in order to
































































Figure 1 Intratracheal DHA enhances survival following
bleomycin injury. Mice were pretreated with DHA (6.25 mg/kg BW)
or PBS 4 days prior to bleomycin injury. A. DHA-pretreated mice did
not lose any weight after bleomycin injury where as the PBS-pretreated
mice lost nearly 10% of their body weight (Bleomycin dose: 1.5 U/kg
BW; PBS, n = 17; DHA, n = 15). B. Survival curve for PBS and DHA
groups (Bleomycin dose: 1.5 U/kg BW; PBS, n = 18; DHA, n = 15).
C. Survival curve for PBS and DHA groups (Bleomycin dose: 2.5 U/kg
BW; PBS, n = 9; DHA, n = 10). Values are means ± SM. ❊ P < 0.05,
❊❊ P < 0.01, ❊❊❊ P < 0.001.
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lized direct pulmonary delivery [40]. The optimum dose
and timing of DHA was determined by a pilot study and
other published DHA studies [28,41]. Thus intratracheal
DHA or PBS was administered to mice 4 days prior to
intratracheal bleomycin. The mice displayed no adverse
effects from the administration of either the DHA or PBS
on day 0 (4 days after DHA or PBS but before bleomycin).
After bleomycin injury, mice pretreated with DHA had
significantly less weight loss (Figure 1A). In addition, there
was a significant increase in survival for the DHA-
pretreated groups compared to the PBS (Figure 1B-C).
This survival advantage occurred with both low dose
(100% vs 61%) and high dose (90% vs 11%) bleomycin
(Figure 1B-C). Thus, pre-treatment of mice with intratra-
cheal DHA prior to bleomycin significantly protected the
animals’ health.
Intratracheal DHA mitigates bleomycin-induced lung
fibrosis
In order to determine if the improved survival after
bleomycin injury in DHA-pretreated mice was due to de-
creased fibrosis, histological examination and lung func-
tion measurement were performed at 14 and 21 days after
bleomycin. The PBS-bleomycin-treated lungs demon-
strated substantially increased fibrosis and inflammation
on days 14 and 21 days (Figure 2A-D). In contrast, there
was markedly less fibrosis and inflammation in DHA-
pretreated mice and their lung structure showed only
minimal damage (Figure 2A-D). Quantification of the
histological sections after bleomycin injury demonstrated
significant differences in the histology scores between
DHA and control groups on days 14 and 21 after bleo-
mycin injury (Figure 2E) [39]. There was no difference
in the baseline (Day 0) histology of PBS- and DHA-
pretreated mice (data not shown).
Lung mechanics focused on the changes in lung tissue
elastance (H) and tissue damping (G) from the conven-
tional forced oscillation technique [38,42]. Tissue elas-
tance reflects the stiffness of the lung and tissue damping
reflects the energy dissipation in the lung tissues. Al-
though there was no significant difference between the
lung tissue elastance of PBS and DHA-pretreated groups
on day 7 after bleomycin injury, there were marked de-
creases in both the tissue elastance and damping in the
DHA-pretreated mice on days 14 and 21 (Figure 3). Over-
all, not only did DHA prevent histological fibrosis, it also
prevented the decreased compliance of the lungs asso-
ciated with fibrosis and inflammation.
DHA prevents bleomycin-induced lung inflammation
In order to determine if the effects of DHA were due to
a decreased inflammatory response to the bleomycin, we

































































Figure 2 (See legend on next page.)
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Figure 2 Intratracheal DHA mitigates bleomycin-induced lung fibrosis. Hematoxylin-eosin staining of lung tissue on days 14 (A) and 21 (B).
Masson’s trichrome staining of lung tissue on days 14 (C) and 21 (D). E. Ashcroft score of tissue damage on days 14 and 21. ❊❊ P < 0.01 (For
day 14: n = 5 and section = 15 for PBS group, n = 7 and section =21 for DHA group; for day 21: n = 7 and section = 21 for PBS group, n = 10 and
section = 30 for DHA group).
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jury. On day 0 (4 days after DHA or PBS but before bleo-
mycin), the total cell count was similar in the DHA- and
PBS- pretreated BALF but there was a slight increase
in the numbers of macrophages in the DHA group
(Figure 4A-D). In response to bleomycin, both groups
initially responded similarly on days 3 and 7 with a mild
increase in total BALF cells (Figure 4A). However, begin-
ning on day 14 and persisting until day 21, the PBS-
pretreated mice had a marked increase in BALF total cells
that was absent in the DHA-pretreated animals. Further-
more, the differential of the BALF cells differed markedly
as the DHA-pretreated mice had significantly less neutro-
phils and lymphocytes beginning on day 7 and continuing
through day 21 (Figure 4C-D).
Similar results were also noted for the cellular infiltrate
in the total lung parenchyma as analyzed by flow cytome-
try (Figure 4E-I). Compared with the PBS-treated mice,
DHA-pretreated mice revealed a blunted response in
T cells (both CD4+ and CD8+) and neutrophils (Ly6G+)
(Figure 4E-I). Interestingly, we also noted a significant de-
crease in lung dendritic cells (CD11Chi MHC-IIhi) after
DHA exposure (Figure 4H). Thus, DHA pre-treatment
blunted bleomycin-induced cellular inflammation in BALF
and lung tissue most notably by inhibiting accumulations
of neutrophils, T cells and dendritic cells.
DHA inhibits bleomycin-induced inflammatory cytokines
and eicosanoids
In order to determine how DHA may inhibit bleomycin–
induced lung inflammation, fibrosis and mortality, we in-
terrogated the BALF from DHA- or PBS- pretreated mice
on serial days after bleomycin injury. DHA significantlyA



















Figure 3 Intratracheal DHA mitigates bleomycin-induced lung restrict
on days 14 and 21 as an indication of lung stiffness (restriction) post bleom
for day 7: n = 4 for both groups; for day 14: n = 5 for PBS group, n = 7 DHAimpaired IL-6 expression in BALF after bleomycin
(Figure 5A). In addition, there was a marked alteration in
IL-10 expression. In PBS-pretreated mice, there was a
continuous decrease in BALF IL-10 after bleomycin injury
(Figure 5B). In contrast, in DHA-pretreated mice, al-
though these was an initial dip in IL-10 on day 3 after in-
jury, the IL-10 levels rebounded and remained persistently
high starting on day 7 (Figure 5B). Of note, we were un-
able to measure significant levels of IFN-γ, IL-33, TNF-α
or IL-1β in either DHA- or PBS- treated mice (data not
shown). We also evaluated changes in eicosanoid media-
tors PGE2 and LTB4. Although PGE2 levels in both
groups initially increased, DHA-pretreated animals
quickly displayed decreased levels of PGE2 by day 14 after
injury (Figure 5C). Interestingly, LTB4 levels remained
quite low in the DHA-pretreated mice but trended to peak
in the PBS-pretreated mice on day 7 after bleomycin
(Figure 5D). Thus, DHA pre-treatment decreased the pro-
inflammatory IL-6 and LTB4 by day 7 and PGE2 at later
time points but increased the anti-inflammatory IL-10
after bleomycin injury.
Discussion
Pulmonary fibrosis is a chronic, progressive interstitial
lung disease with a poor prognosis for which there is no
effective treatment [1,43]. The lack of therapy is in part
due to the limited knowledge concerning the pathoge-
nesis of the disease. However, many recent studies have
implicated dysregulated immune responses and aberrant
wound healing as playing key roles in the etiology of
lung fibrosis. As n-3 polyunsaturated fatty acids, such
as DHA (docosahexaenoic acid), have the capacity to

















ion. Assessment of tissue elastance (H) (A) and tissue damping (G) (B)
ycin injury. ❊ P < 0.05, ❊❊ P < 0.01 (For day 0: n = 4 for both groups;
group; for day 21: n = 7 for PBS group, n = 10 for DHA group).



























































































































































































Figure 4 Intratracheal DHA mitigates bleomycin-induced lung inflammation. A-D. BALF total cell and differential cell counts in PBS-pretreated
mice (grey bars) and DHA-pretreated mice (black bars) (n≥ 5 for both groups at each time point). E-I. Flow cytometry analysis of total lung cells in PBS
vs DHA pretreated groups. ❊ P < 0.05, ❊❊ P < 0.01, ❊❊❊ P < 0.001(for days 0 and 3: n≥ 3 for each group; for days 7, 14 and 21: n≥ 5 for each
group).
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brosis. We demonstrate the ability of intratracheal DHA
to mitigate bleomycin-induced lung injury. Specifically,
mice pretreated with DHA have significantly less weight
loss, mortality, lung inflammation, histology damage and
physiologic derangements in lung function. Mechanisti-
cally, DHA pretreatment appears to mitigate lung dam-
age by suppressing lung inflammatory cells, decreasing
IL-6, LTB4, PGE2 and increasing IL-10. Thus, our fin-
dings demonstrate that intra-tracheal administration of
the n-3 polyunsaturated fatty acid, DHA, protected mice
from the development of bleomycin-induced pulmonary
inflammation and fibrosis. Our data suggest further in-
vestigations into the role of n-3 polyunsaturated fatty
acids in the treatment of lung fibrosis.
While many studies claimed the beneficial effects of
fish oil, we chose to look only at the pure n-3 PUFA.Given the contradictory results of many recent studies
using fish oil, a complex mixture of polyunsaturated
fatty acids as well as a range of other unsaturated and
saturated fats, a study of such a complex material would
have little chance to define specific protective pathways
in lung fibrosis. Indeed, similar discrepancy also oc-
curred in the studies about the effect of fish oil on
bleomycin-induced pulmonary fibrosis [44,45]. Although
the mechanism by which n-3 PUFAs decreased inflam-
mation is unclear, changes in the composition of the cell
membrane have been implicated. The cell membrane
composition of inflammatory cells in subjects fed n-3
PUFA-rich diets demonstrate increased amount of n-3
PUFAs thus altering the fatty acid composition of cellu-
lar phospholipids [36,46,47]. Although little is known
about the effects of these cellular modifications by DHA,
Fan et al. have suggested that the impacts of n-3 PUFAs




































































Figure 5 Intratracheal DHA alters bleomycin-induced cytokines and eicosanoid mediators. Levels of IL-6 (A), IL-10 (B), PGE2 (C) and LTB4
(D) in BALF from PBS vs DHA pretreated bleomycin injured mice. ❊ P < 0.05, ❊❊ P < 0.01 (n≥ 4 for each group at each time point).
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signal transduction (18). Our study is unique in that we
directly administered the DHA to the target organ, the
lungs. We gave the DHA 4 days before the bleomycin to
allow significant time for the n-3 PUFA to integrate into
the membrane phospholipid and mitigate any effect due
only to the intratracheal instillation itself. As previous
studies have demonstrated that the integration of the
DHA into the membrane is stable for at least 8 weeks,
thus the impact of the DHA on membrane composition
would still be maintained during the 21 days after bleo-
mycin injury [36].
Although no animal model of lung fibrosis is perfect,
the bleomycin model is a well-established, extensively
studied, reproducible model of murine lung fibrosis that
can be interrogated to reveal potential mechanisms under-
lying human fibrotic lung disorders [48-51]. DHA pre-
treatment significantly mitigated the fibrotic changes
induced by bleomycin on examination of histology, lung
function and mortality. Both panorama and high power
images of lung tissue demonstrate a clear decrease in
fibrosis in the DHA-treated animals. The ability of n-3
PUFAs to inhibit inflammation has been suggested in
numerous diseases such as Crohn’s Desease and rheuma-
toid arthritis [11,13]. Indeed, we demonstrate that DHA
also prevented the bleomycin-induced inflammatory cells
in both BALF and lung tissue, in particular there was a
marked decrease in lymphocytes and neutrophils in the
lungs of DHA-pretreated animals.We also demonstrate a change in the inflammatory
cytokine profile in DHA-pretreated bleomycin injured
mice. While there is a marked rise in the IL-6 level of
PBS-bleomycin-treated mice, the DHA-pretreated mice
have no increase in IL-6 levels. This is in keeping with
recent studies displaying that DHA inhibited macro-
phage IL-6 production [31,34]. Although the role of IL-6
in pulmonary fibrosis is only emerging, Saito et al. have
reported less severe bleomycin-induced lung injury in
IL-6-deficient mice [52]. Additionally IL-6 has been im-
plicated in mediating the phenotypic conversion of fibro-
blast to myofibroblast via up-regulation of α-SMA [53].
As lung myofibroblasts appear to play a role in lung
fibrosis, DHA may be mitigating the development of
fibrosis by inhibiting bleomycin induced IL-6 [54-56].
Lastly, blocking of IL-6 receptor has also been shown to
alleviate bleomycin-induced skin fibrosis [57].
In addition, we also demonstrate changes in IL-10 ex-
pression in DHA-treated animals. In the PBS-bleomcyin-
treated controls, the IL-10 levels progressively decrease as
the inflammation and fibrosis develop and are quite low
by day 21. However, in the DHA-bleomcyin-treated ani-
mals, although the IL-10 levels dip on day 3, they begin to
increase thereafter and are back to or above baseline levels
by days 14 and 21. The exact role of IL-10 in pulmonary
fibrosis is unclear. While gene delivery of IL-10 has been
showed to attenuate pulmonary fibrosis other investi-
gators have found it only inhibited inflammation, but not
fibrosis [58,59]. Regardless, in our study we see both
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with decreased inflammation and fibrosis in the DHA-
pretreated animals.
Leukotrienes (LTs) and prostaglandin (PGs) belong to a
family of bioactive lipids, called eicosanoids that are pro-
duced from arachidonic acid by 5-lipoxygenase and cyclo-
oxygenase [6]. Eicosanoid mediators have been suggested
to be involved in a host of inflammatory diseases, and
their potential role in pulmonary fibrosis has been increa-
singly recognized [6,10,60]. Incorporation of n-3 PUFAs,
in place of arachdonic acid into cell membranes, results in
decreased production of eicosanoid mediators as n-3
PUFAs are poor substrates for 5-lipoxygenase and cyclo-
oxygenase [36,37]. Several human studies reveal that
dietary n-3 PUFA supplementation significantly decreased
PGE2 and LTs production by human immune cells [36,61].
Indeed, our data demonstrating decreased PGE2 at later
time points after bleomycin injury in the DHA-treated
animals is consistent with studies demonstrating that
DHA inhibit PGE2 synthesis [27,32,33,35].
Currently, the role of PGE2 in pulmonary fibrosis is
unclear. Both human and animal studies alike have
demonstrated seemingly contradictory data concerning
the beneficial or detrimental effects of prostaglandins in
lung fibrosis [9,10,62-65]. While several investigators have
demonstrated that exogenously increasing PGE2 levels
protected mice from bleomycin-induced lung injury,
others have suggested that PGI2, not PGE2, is the pro-
tective prostaglandin [9,10,63]. Our finding of lower levels
of PGE2 in DHA-treated mice on days 14 and 21, as the
acute inflammation recedes and the fibrosis begins, may
indicate that PGE2 may be pathogenic in the fibrotic
process. Our study differs from other studies purporting
the benefits of PGE2 in mitigating lung fibrosis in many
ways. We are administering the DHA, not PGE2, thus
affecting upstream pathways not just PGE2 levels. We
measure PGE2 in BALF at many time points during the
acute inflammation and subsequent fibrosis. Other studies
either do not measure PGE2 content or only at early time
points where we too see no difference [9,63,66]. Finally we
are administering the DHA directly to the lungs thus
avoiding any of the off target anti-inflammatory effects of
administering PGE2 via subcutaneous pumps [9,63] Al-
though Ivanova et al. did administer PGE2 by aerosolized
liposomes, no BALF levels were reported making it diffi-
cult to compare directly to our data [66].
Furthermore, in a model of bleomycin-induced skin
fibrosis, investigators showed mice lacking the PGE2
(mPGES-1 null mice) were resistant to bleomycin-
induced skin fibrosis [67]. In our study, we see similar
levels of PGE2 in the first 7 days after bleomycin injury
but these levels markedly decrease in the DHA-treated
mice at late time points. Although the decreased PGE2
levels may be mirroring the decreased inflammation andfibrosis at later time points, the relative lack of it may also
prevent fibrosis as suggested in the studies showing less
bleomycin-induced skin fibrosis in PGE2-deficient mice.
Interestingly, our data also suggested there is less LTB4 in
the DHA-pretreated mice. This is in keeping with the lit-
erature that demonstrated decreased bleomcyin-induced
fibrosis in mice deficient in leukotrienes or in those mice
where LTB4 receptor is blocked [7,60]. Thus, as DHA is
known to modify cell membrane composition and thus
eicosanoids metabolism, in our model DHA pre-treatment
may be mitigating the bleomycin-induced lung inflamma-
tion and fibrosis by altering the eicosanoids, LTB4 and
PGE2.
Conclusion
In conclusion, our findings demonstrate that intra-tracheal
administration of the n-3 polyunsaturated fatty acid, DHA,
protected mice from the development of bleomycin-
induced pulmonary inflammation and fibrosis. Our data
suggest further investigations into the role of n-3 polyun-
saturated fatty acids in the treatment of lung fibrosis.
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